Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead ...
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $39.77 which represents a decrease of $-2.37 or -5.62% from the prior close of $42.14. The stock opened at $42.05 and touched a ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...
Short interest for healthcare stocks in S&P 500 stayed flat in October vs. September, while Moderna continued to be most shorted stock of the month. The average short interest for S&P 500 Health ...
On Friday, Moderna Inc (MRNA) stock saw a decline, ending the day at $46.83 which represents a decrease of $-3.45 or -6.86% from the prior close of $50.28. The stock opened at $50.42 and touched a low ...
Investing.com -- Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on ...
This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback